Proteins and Peptides

14 July 2014

Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation

11 July 2014

Sigma-Tau Rare Disease Submits Application to the European Medicines Agency (EMA) for Use of PegylatedL-Asparaginase (Oncaspar®) in the Treatment of Acute Lymphoblastic Leukaemia

11 July 2014

Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe1

10 July 2014

OPKO’s Long-Acting Clotting Factor VIIa-CTP Receives Positive Opinion For Three Orphan Drug Designations in Europe

10 July 2014

Adocia Announces Approval to Start a Phase IIa Clinical Study of HinsBet®, its Fast-acting Human Insulin, in Type 1 Diabetes

8 July 2014

Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo for Phase 3 Studies of Factor Xa Inhibitor Antidote, Andexanet Alfa, and Edoxaban

8 July 2014

FDA Approves NovoSeven® RT for the Treatment of Glanzmann’s Thrombasthenia (GT) With Refractoriness

8 July 2014

FDA Accepts Sanofi’s New Drug Application for Basal Insulin Toujeo

1 July 2014

Stage 3 Phase 2 Study of DARPin Abicipar Pegol (previously MP0112) Supports Progressing to Phase III Development Program

1 July 2014

Ipsen submits marketing authorization applications in the US and Europe for Somatuline® (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

1 July 2014

Synageva BioPharma(TM) Reports Positive Top-Line Results From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency

30 June 2014

Nora Therapeutics Presents Phase 1 Data on NT100 at the European Society of Human Reproduction and Embryology Annual Meeting

30 June 2014

Allergan Announces R&D Pipeline Update and U.S. FDA Approval; Company to Host Conference Call Today, Monday, June 30th at 10:30 AM ET

28 June 2014

MannKind Corporation Announces FDA Approval of AFREZZA(R); A Novel, Rapid-Acting Inhaled Insulin for the Treatment of Diabetes

28 June 2014

Lundbeck provides update on the development program for desmoteplase

27 June 2014

Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting

27 June 2014

Janssen Submits EU Marketing Application for VELCADE® (bortezomib) in Mantle Cell Lymphoma

27 June 2014

CHMP Recommends Lilly and Boehringer Ingelheim’s Investigational New Insulin Glargine Product for Approval in the European Union

26 June 2014

Nora Therapeutics Announces Initiation of Phase 2 RESPONSE Research Study

25 June 2014

Flamel Technologies Announces Positive Preclinical Results For Its Once-a-Week Formulation of Exenatide

25 June 2014

Sobi files for EU approval of Xiapex for Peyronies disease

24 June 2014

Zealand provides an update on activities relating to danegaptide for the protection of cardiac tissue against reperfusion injuries

24 June 2014

OPKO Announces Positive Interim Six-Month Lagova™ (hGH-CTP) Phase 2 Data in Pediatric Growth Hormone Deficiency Disorder

24 June 2014

Ferring Pharmaceuticals and Roche collaborate to develop personalised infertility treatment

23 June 2014

Versartis Presents Positive Six Month VRS-317 Phase 2a Clinical Study Results

22 June 2014

Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo

22 June 2014

New phase 3a liraglutide 3 mg data showed positive impact on cardiovascular risk markers and fewer people progressing to prediabetes compared with placebo in adults with obesity

21 June 2014

Teijin Pharma to Develop Sheet-type Fibrin Sealant for Surgical Operations

19 June 2014

Apitope Progresses Graves’ Disease Treatment

18 June 2014

Hetero Launches Darbepoetin Alfa, a Much Needed Biosimilar Anemia Treatment in India

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Report Package: “Drug the Undruggable” Technologies

DLL3-Targeted Immunotherapy Candidates Pipeline Review

TROP-2-Targeted Immunotherapy Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review